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Abstract
Background: Loss to follow-up is a major challenge of antiretroviral treatment (ART) programs in sub-Saharan
Africa. Our objective was to a) determine true outcomes of patients lost to follow-up (LTFU) and b) identify risk
factors associated with successful tracing and deaths of patients LTFU from ART in a large public sector clinic in
Lilongwe, Malawi.
Methods: Patients who were more than 2 weeks late according to their last ART supply and who provided a
phone number or address in Lilongwe were eligible for tracing. Their outcomes were updated and risk factors for
successful tracing and death were examined.
Results: Of 1800 patients LTFU with consent for tracing, 724 (40%) were eligible and tracing was successful in 534
(74%): 285 (53%) were found to be alive and on ART; 32 (6%) had stopped ART; and 217 (41%) had died. Having a
phone contact doubled tracing success (adjusted odds ratio, aOR = 2.1, 95% CI 1.4-3.0) and odds of identifying
deaths [aOR = 1.8 (1.2-2.7)] in patients successfully traced. Mortality was higher when ART was fee-based at
initiation (aOR = 2.3, 95% CI 1.1-4.7) and declined with follow-up time on ART. Limiting the analysis to patients
living in Lilongwe did not change the main findings.
Conclusion: Ascertainment of contact information is a prerequisite for tracing, which can reveal outcomes of a
large proportion of patients LTFU. Having a phone contact number is critical for successful tracing, but further
research should focus on understanding whether phone tracing is associated with any differential reporting of
mortality or LTFU.
Background
The large proportion of patients lost to follow-up
(LTFU) is one of the major challenges to the ongoing
success of antiretroviral treatment (ART) programs in
sub-Saharan Africa [1-3]. Data from a network of ART
programs in resource-limited settings showed that on
average 21% of patients had been lost from programs in
the first six months after starting ART [3]. A systematic
review found that about 40% of patients in sub-Saharan
Africa were lost at two years, with large variation in
retention rates between programs [2]. A further
systematic review and meta analysis of studies, which
determined the vital status of patients LTFU after start-
ing ART, found that mortality among successfully traced
patients in African ART program ranges from 12% to
87%, with a combined mortality of 46% [4].
A better understanding of risk factors for tracing suc-
cess and mortality among patients LTFU could help to
develop targeted interventions to prevent LTFU and
reduce mortality; risk factors for mortality have not been
evaluated systematically [4]. ART clinics face serious
operational challenges to trace patients LTFU. True out-
comes of patients LTFU are difficult to assess: definitions
and intervals that trigger tracing vary, active tracing
of patients is labor- and time-intensive, and in 34% of
traced patients the vital status still remains unknown [4].
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Different tracing methods and their success rates are
poorly described. Confronted with this, ART-clinics in
settings with high demand for ART but with limited
human resources may decide to focus on equipping
patients initiating ART with good knowledge
about adherence rather than investing limited resources
in efforts to follow-up mobile patients in their com-
munities [5].
In 2003, adult HIV prevalence in Malawi was esti-
mated at 11.4% and about 240,000 people were in need
of ART [6]. In response, Malawi’s free national ART
program started in June 2004 as a generalized public
health approach [7-9]. To improve ART adherence and
program retention, the national ART guidelines recom-
mend “frontloading” patients with information on the
implications of ART treatment before initiation,
encouraging peer support by a family member or desig-
nated guardian, and methodical documenting patient’s
outcomes at every visit [10-12]. By the end of 2005 mor-
tality and loss to follow-up (defined as patients not seen
in the clinic for more than 60 days after anticipated
expire of individual drug supply) in the national cohort
was 10% and 8%, respectively [13].
In 2005, at the height of rapid scale-up of ART in
Malawi, we set out to determine the true outcomes of
patients LTFU up from ART at Lighthouse, a major
provider of HIV-related services for adults and children
in Malawi, and to identify risk factors for successful tra-
cing and death.
Methods
Setting
The Lighthouse Trust (Lighthouse) is part of Kamuzu
Central Hospital, the tertiary health facility of Malawi’s
central region within the capital Lilongwe and has
offered HIV counseling and testing, clinical and home-
based care since 2002 [14]. From 2002 to 2004, Light-
house was the only public-sector ART clinic for the cen-
tral and northern region and about 60 patients started
each month on a fee-basis ("paying period”). In June
2004, the Ministry of Health opened 60 ART clinics in
the public sector throughout Malawi, and Lighthouse
began offering free ART, with a target of starting 150
new patients on ART per month.
Registration, ART-initiation and follow-up
Lighthouse has maintained electronic data for all initial
and follow-up visits since its inception. Details of proce-
dures for clinic registration and ART initiation during
the “paying period” have been described elsewhere [15].
In line with the 2003 national ART-guidelines, Light-
house implemented standardized procedures for patient
management and monitoring[10]. In short, HIV-infected
patients register at the clinic with name, age, sex, place
of residence, phone number and are asked consent to be
contacted if they miss their appointment. After registra-
tion, clinicians treat active opportunistic diseases and
provide cotrimoxazole prophylaxis. Patients in WHO
stage 3 and 4 or with a CD4 count of below 200 cells/μl
(until 2005) or below 250 cells/μl (from 2006) are eligi-
ble for ART. For children (as defined as persons 0-14
years old at the time of ART initiation) the age-depen-
dent absolute CD4 count value thresholds for severe
immunosuppression were used. The majority of children
started at an age, when adult normal values are reached.
To initiate ART, patients are required to attend a group
education session and then are started on a fixed dose
combination regimen of d4T/3TC/NVP with a two
week lead-in phase. Thereafter, patients are seen
monthly and receive an ART supply for 30 days. Pill
counts are recorded at each visit to assess adherence.
Appointments are given according the remaining pills
and the new supply. After attending a refresher adher-
ence counseling session, patients are eligible to receive a
supply for 60 days and visit the clinic every 2 months. If
acutely ill, patients are referred to Kamuzu Central Hos-
pital wards. Clinic staff updates outcomes on the patient
master card at every visit and the ART register is
updated at least quarterly.
Study population and data collection
Between August and December 2005 we actively traced
patients LTFU, i.e. patients who were at least two weeks
late for a scheduled appointment according to their last
ART supply. We thus included patients with shorter
delays than 60 days proposed by the Malawian national
program guidelines as to evaluate the effect of earlier
tracing on patient outcomes. The study population was
restricted to all patients ever starting ART at the Light-
house clinic until 31st of May 2005. We verified contact
information (phone and place of residence) and whether
patients consented for external tracing; Lighthouse
began collecting this contact information in May 2004,
so patients already LTFU by this time were not traced.
We excluded patients living outside Lilongwe city with-
out a phone number, patients living within Lilongwe
city but without address and phone number and those
who did not consent for tracing.
Using the list of eligible patients, Kamuzu Central
Hospital death registry was cross-checked for Light-
house patients and their date of death, and the ART
register at Mzuzu Central Hospital in the northern
region of Malawi, which opened its ART clinic shortly
before start of the study, was searched for Lighthouse
patients LTFU whose transfer out was not registered.
Study assistants contacted the patients, family mem-
bers or contact persons by phone or in-person. A brief
survey instrument was used to collect vital status and
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relevant information on current ART use, current site of
care, or date of death. All study data were collected on
paper forms and subsequently entered into an electronic
database.
Statistical analysis
We used descriptive analyses to examine demographic
and clinical characteristics and tracing history of patients
LTFU and their outcomes. Outcomes were classified as
patient alive, died or untraceable. Patients found alive
were further categorized as on ART, transferred out to
another ART program or having stopped ART.
We performed logistic regression for both successful tra-
cing and mortality among successfully traced patients to
determine risk factors for these outcomes and, in a second
step, performed a sensitivity analysis restricted to patients
living in Lilongwe. Predictor variables for both models
included gender, age at start of ART (in years; groups 15-
29; 30-39; 40-49; ≥ 50), time period of starting of ART (2
groups: until June 2004, paying for ART; June 2004 or
later, free ART), reason for starting ART (4 groups: low
CD4 count; WHO stage 3; WHO stage 4; other or
unknown), follow-up time from start of ART until the last
patient contact (time of last visit in months: no follow-up;
1-6; 7-12; 13 or later) and providing a telephone contact.
We evaluated adjusted odds ratios that were mutually
adjusted for all other predictor variables.
The day and month of death was commonly unknown
for patients who were traced outside of the health facil-
ities. To evaluate mortality rates since ART initiation in
patients LTFU with known outcomes (i.e., those traced
successfully) we performed sensitivity analysis by step-
wise increasing the presumed date of death by 3 months
between one day after the last contact date and the date
of successful tracing for that patient. Under these differ-
ent scenarios we evaluated mortality among successfully
traced patients using Kaplan-Meier analysis over months
1 to 12 and months 13 to 24. Rates are expressed in
deaths per 100 person-years. All analyses were done
using Stata (version 10.1; Stata Corporation, College Sta-
tion, Texas, USA).
Ethical approval
The study has ethical approval from the National Health
Science Research Committee (NHSRC), the national
ethics committee in Malawi. General measures were
provided in all ART facilities to ensure patient confiden-
tiality, consent for HIV testing and counseling, and sup-
port for those who received a positive HIV test result.
Data collected for this study did not include personal
identifiers. Since the study was partly funded by the U.S.
Centers for Disease Control and Prevention (CDC) and
involved a co-investigator from CDC, the protocol had
to undergo ethics review by CDC. As the study design
and purpose aims at evaluating and improving services,
it was approved and classified as program evaluation, a
type of public health non-research according to CDC
regulations [16].
Results
Recruitment of study participants, baseline characteristics
and outcomes of patients lost to follow-up
Until 31st May 2005, 3846 patients had ever started ART
at the Lighthouse and 1840 (48%) were LTFU, of whom
1800 (98%) had given consent to tracing (Figure 1). For
1076 patients the contact address was outside Lilongwe
and no phone contact was given or was within Lilongwe
and neither phone number nor address was given. From
the list of the patients remaining eligible for tracing, a
review of records in Lilongwe and Mzuzu Central Hos-
pitals revealed vital status of 93 patients, so that 631
patients had to be traced by outreach, either by phone
or in-person. In total we thus evaluated outcomes of
724 patients LTFU that included 659 adults and 65 chil-
dren less than 15 years of age, representing 40% (724/
1800) of all patients LTFU who gave consent for tracing.
Table 1 describes the baseline demographic and clini-
cal characteristics of the study population. Adults and
children had a median age of 36 and 6 years, and the
percentage of females was 53% and 43%, respectively.
The median year of ART start was 2004 and start of
Ever started ART until 31 May 2005: 3846
Outcome other than LTFU 
(Alive, dead, stopped, transfer-out): 2006
LTFU: 1840 (48%)
Identified in other
health facilities: 93 (13%)
Outside Lilongwe city without phone
 or within and no phone or address: 1076 
Targeted by outreach:
 631 (87%) 
No consent to tracing: 40
Consent to tracing: 1800 (98%)
Number of eligible patients: 724 (40%) 
(659 adults; 65 children, age < 15) 
Figure 1 Scheme of recruitment for the tracing study
(N = 724).
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ART was free of charge for most adults (67%) and chil-
dren (80%). The median (IQR) baseline CD4 counts
were 71 cells/μl (22-141) and 184 cells/μl (29-423) and
the most common reason for ART start was WHO
stage 3 in 67% and 89% of adults and children, respec-
tively. The median (IQR) duration of follow-up in the
ART-clinic was 73 days (14-303) and 92 days (13-210),
and 67% and 69% of adults and children were LTFU
within 6 months after ART start. Telephone contact was
available for 47% of adults and 37% of children and 86%
of adults and 89% of children were living in Lilongwe.
Of the 631 patients traced by outreach, 55 (9%) patients
had two and 2 patients had three successive tracing
attempts. Altogether, 389 (57%) tracing attempts were per-
formed in-person and 299 (43%) by phone. First tracing
attempts were successful in 61% of the in-person attempts
(204/336) and 73% (214/295) by phone attempts. Tracing
success declined from 66% (418/631) to 36% (20/55) from
first to second tracing attempt (data not shown).
The updated outcomes after tracing are given in
Table 2. In total, of those eligible for tracing, 534 (74%)
patients LTFU were successfully traced. These included
486 adults and 48 children, of whom 201 (41%) and 16
(33%) respectively, were found to be dead. Among the
317 patients found to be alive, 285 (90%) were still on
ART (157 at Lighthouse and 128 at another ART clinic)
and 32 (10%) had stopped ART.
Factors associated with successful tracing in adult
patients
The percentage successfully traced was 81.4% and 67.0%
(P < 0.001) for patients with and without a phone con-
tact, respectively. Controlling for gender, age, treatment
period, reason for start of ART and time of the last
clinic visit from ART start, having a phone number
doubled the odds of successful tracing (aOR 2.07, 95%
CI: 1.42-3.01, P < 0.001) (Table 3). Other factors, includ-
ing reasons for start of ART (P = 0.39) and follow-up
time until the last clinic visit (P = 0.94) were not asso-
ciated with tracing success. After restricting the analysis
to patients living in Lilongwe the results stayed mostly
the same and availability of a phone number remained
the major risk factor (data not shown).
Mortality and risk factors for mortality in successfully
traced adults
Mortality rates in successfully traced patients between
months 1 and 12 after start of ART were 58 (95% CI:
50-67), 50 (95% CI: 43-58) and 45 (95% CI: 38-53) per 100
person-years, when allowing a maximal time between the
date of last visit and the presumed death date of 3, 6 and 9
months, respectively. Between months 13 and 24 the
respective mortality rates were 19 (95% CI: 12-30), 20 (95%
CI: 13-31) and 27 (95% CI: 19-39) per 100 person-years.
Table 4 shows the crude percentage mortality and
adjusted odds ratios of death in relation to risk factors.
The percentage of deaths was 64.6% in patients with no
follow-up following ART initiation as compared to 50%,
16.7% and 19.8% in those with a last visit in months 1 to
6, months 7 to 12 and months 13 or later, respectively.
The corresponding adjusted odds ratios were 0.55 (95%
CI: 0.31-0.96), 0.073 (95% CI: 0.03- 0.18), and 0.058 (95%
CI: 0.024-0.14), indicating declining mortality with
increasing follow-up time (P < 0.0001). The proportion
Table 1 Demographic and clinical characteristics of
patients included in the tracing study (N = 724)
Parameter Adults Children
Number (% of total) 659 (91%) 65 (9%)
Age (median, IQR) 36 (31-43) 6 (3-10)
Number (%) of females 351 (53%) 28 (43%)
Year of ART start (median; range) 2004 (2000-
2005)
2004 (2002-
2005)
ART free of charge at start (after 10
June 2004)
440 (67%) 52 (80%)
CD4 at start of ART (median, IQR)* 71 (22-141) 184 (28-423)
Reason ART start
Low CD4 count 72 (11%) 3 (5%)
WHO stage 3 444 (67%) 58 (89%)
WHO stage 4 124 (19%) 3 (5%)
Transfer in 3 (0.5%) 0 (0%)
Not recorded 16 (2.5%) 1 (1%)
Days of follow up on ART (median, IQR) 73 (14-303) 92 (13-210)
Number (%) by time period since start of ART
No follow-up 109 (17%) 13 (20%)
Months 1 to 6 331 (50%) 32 (49%)
Months 7 to 12 78 (12%) 12 (19%)
Months 13 or later 141 (21%) 8 (12%)
Number (%) with telephone contact ☎ 307 (47%) 24 (37%)
Residence in Lilongwe 567 (86%) 58 (89%)
* missing in 30 adults and 3 children; ☎ home, cell and/or work phone.
Table 2 Success of tracing and outcomes in patients
successfully traced
Outcome Total Adults Children
Overall 724 659 65
Successfully traced 534 (74%) 486 (74%) 48 (74%)
Found to have died
(% of those successfully
traced )
217 (41%) 201 (41%) 16 (33%)
For patients found to
be alive
317 285 32
On ART at Lighthouse
(% of alive)
157 (50%) 135 (47%) 22 (69%)
Transfer-out, on ART
(% of alive)
128 (40%) 127 (45%) 1 (3%)
Stopped ART
(% of alive)
32 (10%) 23 (8%) 9 (28%)
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of recorded deaths was higher among successfully traced
patients with a phone contact (43.6%) as compared to
those without a phone (39%; aOR 1.79, 95% CI: 1.19-
2.71, P = 0.005). The adjusted odds of death were further
higher among patients that initiated ART during the pay-
ing period as compared to the free period [aOR = 2.28
(1.10-4.72); P = 0.022]. Gender, age group and reason for
start of ART were not strongly associated to the risk of
death in successfully traced patients. The sensitivity ana-
lysis restricting to patients living in Lilongwe did not
reveal major changes of the results and time of last visit
since ART start and availability of a phone number
remained the major risk factors for mortality among suc-
cessfully traced adult patients (data not shown).
Discussion
Dedicated tracing studies of patients LTFU are an impor-
tant instrument to improve quality of care as well as out-
come evaluation of ART programs in sub-Saharan Africa.
In the present study in Lilongwe, Malawi, only 40% of
patients LTFU who gave consent could be traced since
contact information was not available for many and field
tracing attempts outside Lilongwe were infeasible. How-
ever, outcomes were successfully updated in 74% of those
traced. Among those successfully traced, 41% of adults
and 33% of children had died, most commonly in the
first six months following ART initiation. Among
patients found to be alive, 92% of adults and 72% of chil-
dren were still taking ART. The availability of a phone
contact improved the chances of successful tracing and
identifying outcomes in patients LTFU. As a result of this
study, we introduced regular ascertainment of contact
information for each patient at the first clinic visit,
recommended patients living outside Lilongwe to register
at ART clinics closer to their homes and are now able to
successfully trace 85% of patients LTFU [17].
A recent systematic review and meta analysis of stu-
dies that traced patients LTFU to ascertain their vital
status in sub-Saharan African ART programs, which
included Lighthouse, showed that on average 46% of
Table 3 Risk factors for successful tracing in adults lost
to follow-up. Odds ratios are derived from logistic
regression; P-values using likelihood ratio tests (N = 659)
Parameter % traced
(95% CI#)
Adjusted
OR (95% CI)
P
Gender 0.34
Female 73.8 (68.9-78.3) 1.20 (0.83-1.73)
Male 73.7 (68.4-78.5) 1
Age group 0.11
15-29 63.9 (54.7-72.4) 1
30-39 74.2 (68.7-79.2) 1.59 (0.99-2.55)
40-49 78.5 (72.0-84.1) 1.91 (1.12-3.24)
≥ 50 76.2 (63.8-86.0) 1.71 (0.83-3.5)
Reason start ART 0.39
Low CD4 count 72.2 (60.4-82.1) 1
WHO stage 3 73.9 (69.5-77.9) 1.15 (0.64-2.04)
WHO stage 4 71.8 (63.0-79.5) 1.07 (0.54-2.12)
Other/unknown 89.5 (66.9-98.7) 3.38 (0.7-16.43)
Time of last visit* 0.94
No follow-up 72.5 (63.1-80.6) 1
Months 1 to 6 71.3 (66.1-76.1) 0.95 (0.57-1.57)
Months 7 to 12 76.9 (66.0-85.7) 0.92 (0.45-1.89)
Months 13 or later 78.7 (71.0-85.2) 0.77 (0.34-1.74)
Telephone contact < 0.001
None 67.0 (61.9-71.9) 1
Available 81.4 (76.6-85.6) 2.07 (1.42-3.01)
Treatment period 0.13
Paying 79.5 (73.5-84.6) 1.66 (0.85-3.23)
Free ART 70.9 (66.4-75.1) 1
# binomial exact 95% confidence interval.
*Follow up time from start of ART until last patient visit.
Table 4 Risk factors for mortality in adults lost to follow-
up that were successfully traced. Odds ratios are derived
from logistic regression; P-values using likelihood ratio
tests (N = 486)
Parameter % Died
(95% CI#)
Adjusted
OR (95% CI)
P
Gender 0.45
Female 40.2 (34.1-46.4) 0.85 (0.56-1.29)
Male 42.7 (36.2-49.4) 1
Age group 0.64
15-29 42.3 (31.2-54.0) 1
30-39 41.0 (34.2-47.9) 0.99 (0.56-1.77)
40-49 38.0 (30.2-46.3) 1.07 (0.57-1.98)
≥ 50 52.1 (37.2-66.7) 1.57 (0.70-3.50)
Reason start ART 0.091
Low CD4 count 28.8 (17.1-43.1) 1
WHO stage 3 39.3 (34.6-45.5) 1.28 (0.63-2.58)
WHO stage 4 56.2 (45.3-66.7) 1.99 (0.88- 4.52)
Other/unknown 28.4 (10.3-55.9) 0.55 (0.15-2.03)
Time of last visit * < 0.0001
No follow-up 64.6 (53.0-75.0) 1
Months 1 to 6 50.0 (43.4-56.6) 0.55 (0.31-0.96)
Months 7 to 12 16.7 (8.29-28.5) 0.073 (0.030-0.18)
Months 13 or later 19.8 (12.9-28.5) 0.058 (0.024-0.14)
Telephone contact 0.005
None 39.0 (32.7-45.5) 1
Available 43.6 (37.4-50.0) 1.79 (1.19-2.71)
Treatment period ‡ 0.022
Paying 30.5 (23.7-37.9) 2.28 (1.10-4.72)
Free ART 47.4 (41.8-53.1) 1
# binomial exact 95% confidence interval.
*Follow up time from start of ART until last patient visit.
‡Adjusted odds ratio for treatment period is reversed from the crude odds
ratio (crude OR = 0.49), due to confounding by time of last visit (for detail,
see Additional file 1).
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those traced were found to have died [4]. The review
also noted the scarcity of information on risk factors for
successful tracing as well as death in patients LTFU as a
major limitation of existing surveys. We identified short
follow-up time on ART as the strongest predictor for
high risk of death in successfully traced patients.
Patients with no follow-up visit or a last visit in the first
6 months showed 50% to 65% mortality as compared to
less than 20% mortality in those seen last after 6 months.
In Uganda, deaths of patients LTFU were examined
depending on the period from their last clinic visit and
rates were highest early after the last visit (mortality of
115, 42 and 21 per 100 person years after 1, 2 to 6, and
after 6 months since the last visit, respectively) [18].
These findings suggest that an earlier start of active tra-
cing of patients that missed a scheduled visit date, espe-
cially when loss to follow occurred shortly after ART
initiation, may help to reduce early mortality.
Studies examining associations between baseline char-
acteristics and tracing success or death show conflicting
results making targeted interventions to prevent LTFU
more difficult. While we and others did not find a strong
relation between age, sex and tracing success [18], in
Zambia, a higher proportion of men were untraceable
[19]. Advanced disease stage at baseline measured by
WHO stage in our study or pre-ART CD4 count [18]
were also not associated with tracing success. With
respect to identifying mortality through tracing, Zambian
patients who died were older, more likely to be TB/HIV
co-infected, had lower BMI, advanced WHO stages and
surprisingly, had higher CD4 count [19]. In contrast,
advanced WHO stages were not associated with death
among our patients LTFU and low CD4 count was asso-
ciated with higher mortality of patients LTFU in Uganda
[18]. Additionally, an earlier analysis of our dataset
showed a lower median CD4 count in untraceable
patients compared to traceable patients who died, and we
hypothesized that many untraceable patients might have
died in line with the Uganda findings [20].
Our study demonstrated that outcomes, including
deaths, of patients LTFU can be found in records of
other health facilities. Where death registries are opera-
tional, such as in South Africa, conclusive evidence on
vital status of patients not found by active tracing can
be retrieved from record linkage using unique patient
identifiers [21,22]. Therefore, improved information
transfer between facilities may prevent costly and time-
consuming tracing.
In our study, during first tracing attempts, phone tra-
cing was more successful in revealing outcomes than in-
field tracing. The availability of a phone contact appears
an effective way of identifying true outcomes of patients
LTFU and was associated with mortality. However,
tracing methods may ascertain outcomes differently.
On the phone, guardians may not want to admit that
their patients have left the clinic, but will reveal that the
patient has died. Likewise, survivors may be more likely
to have changed their phone number leading to a failed
phone tracing attempt, but not their home address
thereby increasing the likelihood of being found alive
through field tracing. Both scenarios could increase the
proportion of deaths among successfully traced patients
via phone compared to in-person field tracing, as
observed in our study. A study from South Africa found
that 46% of patients LTFU could not be contacted
because of incomplete or missing contact details and
highlights the difficulties of phone tracing in patients
without a permanent residential address, such as sharing
of one cell phone by the entire family and changing of
phone numbers due to theft or expiration of the SIM
card [23]. However, cell phone coverage is increasing in
Malawi and positive experience using phones in patient
follow-up may result in wider use [24]. Therefore, more
information on advantages and limitations of different
tracing methods is needed.
Our findings highlight the importance of maximizing
the potential for early tracing, including soliciting of
patient consent to be traced and maintaining current
contact information for patients who consent to be
traced. Tracing was possible in only 40% of our patients
LTFU, but when attempted, the patient status was veri-
fied in 74%. Nearly all patients LTFU and found to be
alive in our study were still taking ART; more than half
of them in our facility. This may be partly related to the
early initiation of tracing, after being 2-weeks late for
appointment, in a substantial proportion of patients
LTFU. Patients may accumulate leftover tablets from
previous supplies without telling us, receive tablets from
family members on ART or from other clinics, without
our information- this needs to be explored further. As a
result of the present study, the period for patients
becoming eligible for tracing was extended to 3 weeks
and the list of patients LTFU to be traced is now
updated weekly within our routine services as to avoid
unnecessary contacting of returning patients.
Our study has limitations. We traced only 40% of
patients LTFU who consented. This sample may not be
representative of all patients LTFU, as it includes only
patients who had given consent for tracing, had pro-
vided contact information in Lilongwe or had a phone
when living outside, and who were in care by May 2004
and beyond. With increasing delay between LTFU and
tracing, patients or guardians may have been more diffi-
cult to contact, as contact information that can change
over time was not regularly updated. Guardians may
further forget details of patients’ ART or may report
outcomes they perceive desirable by the phone or field
tracers, which could result in under-reporting of the
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outcome “stopping treatment”. In addition, we did not
analyze the period from LTFU and tracing to provide
further information about the importance of this win-
dow period for tracing success and outcomes. Finally,
few data on children LTFU in our sample prevented us
from a separate analysis and more information is needed
to examine the specific features in this age group.
Conclusions
ART programs need to maintain current contact informa-
tion of patients or guardians and should be aware of the
limitations of the tracing method used. They should aim
for early tracing after a missed appointment for ART pick-
up, especially if patients have recently started ART, includ-
ing searching hospital records for patients LTFU. These
interventions may increase the proportion of successfully
traceable patients to return them back to care and reduce
mortality; and improve overall program evaluation.
Additional material
Additional File 1: Table presenting follow-up time from start of ART
until last patient visit and mortality in adults lost to follow-up that
were successfully traced and started ART in the paying (top part;
N = 174) and free ART period (lower part; N = 312). The percentage
of deaths declines with follow-up time in the paying (until 10th June
2004) as well as the free ART period (after 10th June 2004), but given
follow-up time from ART start until the last visit, mortality in the paying
era is consistently higher. This is reflected in the adjusted OR for
comparing paying with free treatment period of 2.28 (95% CI 1.10-4.72)
in Table 4. The adjusted OR is reversed to the crude OR of 0.49, because
of the reversed distribution of patient numbers over the Time-of-last-
visit- periods, which are associated with different rates of mortality.
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